Resmed RMD Insider Ownership

Updated Oct 11, 2026

Over the trailing 12 months, RMD insiders sold $22.26 million worth of shares (94.57K shares) in open-market trades, with no open-market purchases.

• Counted by insider, open-market selling of RMD stock in the past 12 months came from 5 insiders, with no insider buying.
• Michael J. Farrell (Chairman and CEO) was RMD's largest open-market seller in the past 12 months, with $14.6 million of sales (62.91K shares); the latest was on October 7, 2026.
• Away from the open market, RMD insiders received 52.03K shares in stock awards, acquired 76.35K shares through option exercises and conversions and gave up 24.58K shares to cover taxes or exercise prices over the last 12 months.
• Per Business Quant, RMD insiders together hold 795.41K shares based on their latest Form 4 filings, up 3.02% from 772.07K shares at the end of Q2 2026.
• Resmed insiders hold 767.03K shares directly (96.43% of their total) and 28.38K shares (3.57%) indirectly, through entities such as trusts and partnerships.
• The insider holdings in Resmed belong to 17 insiders who have reported on Form 4 within the past two years.
• RMD's largest insider holders by reported holdings are Michael J. Farrell (Chairman and CEO, 481.89K shares), Brett Sandercock (Chief Financial Officer, 83.5K shares) and Peter C. Farrell (Director, 51.8K shares).
• The holding of Michael J. Farrell makes up 60.58% of all shares held by Resmed insiders.
• Institutional holders reported 68.66% of Resmed's outstanding shares for Q2 2026; insiders' latest Form 4 filings put their stake at about 0.55%, and other investors, including the public, hold the remaining 30.79%.
• In the past year, 15 insiders of Resmed submitted 56 Form 4 filings reporting trades, awards or other transactions.
• The insider holdings and trades above for Resmed reflect Form 4 filings through October 8, 2026.